Format

Send to

Choose Destination
  • Showing results for 2017[pdat] AND factors contributing to exacerbating vulnerabilities in global clinical trials. Your search for 2017[pdat] AND Factors cContributing to eExacerbating vVulnerabilities in gGlobal cClinical tTrials retrieved no results.
Front Pharmacol. 2018 Jan 17;8:999. doi: 10.3389/fphar.2017.00999. eCollection 2017.

Factors Contributing to Exacerbating Vulnerabilities in Global Clinical Trials.

Author information

1
Office of Clinical Trials, Brazilian Health Regulatory Agency (Anvisa), Brasília, Brazil.
2
Faculty of Health Sciences, University of Brasília (UnB), Brasília, Brazil.
3
School of Medicine, Health Sciences Education and Research Foundation (Fepecs), Brasília, Brazil.
4
Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Abstract

Background: Although policies and guidelines make use of the concept of vulnerability, few define it. The European Union's directive for clinical trials does not include explanations for or the reasoning behind the designation of certain groups as vulnerable. Emerging economies from lower middle-income countries have, in recent years, had the largest average annual growth rate, as well as increase, in number of clinical trials registered in the US government's database. Nevertheless, careful supervision of research activities has to be ensured. Objective: To describe and analyze the features of the clinical trials involving vulnerable populations in various countries classified by development status and geographic region. Methods: Retrospective study that involved analysis of data obtained from the International Clinical Trials Registry Platform (ICTRP) database between 01/2014 and 12/2014 from countries with (i) highest trial densities during 2005 to 2012, (ii) highest average growth rate in clinical trials, and (iii) greatest trial capabilities. Results: Statistical analysis of this study showed that patients incapable of giving consent personally are 11.4 times more likely to be vulnerable patients than patients who are capable, and that patients in upper-middle-income countries are 1.7 times more likely to be vulnerable patients than patients from high-income countries when participating in global clinical trials. Malaysia (21%), Egypt (20%), Turkey (19%), Israel (18%), and Brazil (17%) had the highest percentages of vulnerable populations involving children. Conclusions: Although the inability to provide consent personally was a factor associated with vulnerability, arbitrary criteria may have been considered when classifying the populations of clinical trials as vulnerable. The EU Clinical Trials Register should provide guidance regarding exactly what aspects or factors should be taken into account to frame given populations as vulnerable, because vulnerability is not applicable to all risk situations.

KEYWORDS:

clinical trials; socioeconomic status; vulnerability; vulnerable population

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center